SUSTAINED RELEASE EFFERVESCENT FLOATING BILAYER TABLETS A REVIEW OF NOVEL APPROACH

GPAT courses

Pharma courses

pharma courses

pharma courses



Future potential for sustained release bilayer floating tablets
Drug release is the major area in the pharmaceutical research work. Through sustained release bilayer floating tablets release can be increased up to 24 hours for drugs incompatible with effervescent floating components, hence this system finds greater advantages over single layer effervescent floating tablets in terms of stability. It is also beneficial in providing gastric retention thereby increasing gastric emptying time as well as increasing bioavailability and reducing dosing frequency which provides better patient compliance. It provides a great opportunity in case of herbal drugs as these drugs can also be given in sustained release effervescent floating bilayer dosage form which provides greater stability to the formulation. Drugs having narrow absorption window such as anti-viral, antibiotic and antifungal can also be given in sustained release floating bilayer dosage form.

REFERENCES:
1) Bolton S, Desai S; Floating sustained release therapeutic compositions; US Patent; 4, 814, 179; March 21; 1989.
2) Desai S.A; Novel Floating controlled release drug delivery system based on a dried gel matrix Network (master’s thesis) Jamaica; NY: St. John’s University; 1984.
3) Dixit N. Floating Drug Delivery System. J Current Pharm Res. 2011;7(1):6-20.
4) Jain N K; Progress in controlled and novel drug delivery systems, First Ed.; 2004,CBS Publishers and Distributors; New Delhi; Bangalore: 84-85.
5) Jimenez-Castellanous N.R, Zia H and Rhodes C.T; Mucoadhesive drug delivery Systems; Drug Development and Industrial Pharmacy; 1993; 19; 143.
6) Mojaverian P, Ferguson R.K, Vlasses P.H; Estimation of gastric residence time of the heidelberg capsules in humans: effect of varying food composition; Scandinavian journal of Gastroenterology; 1985; 89; 392-397.
7) Pujar ND, Gokani RK, Paun JS. Bilayer Tablet – An Emerging Trend. International Journal of Pharmaceutical Research and Development. 2012, 4, 102 – 111.
8) Talukder R and Fissihi R; Gastroretentive delivery systems: A mini review; Drug Development & Industrial pharmacy; 2004; 30(10); 1019-1028.
9) Timmermans J, Andre J.M; Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy; Journal of Pharmaceutical science; 1994; 83; 18-24.
10) Vantrappen G.R, Peeters T.L, Janssens J; The secretory component of interdigestive migratory motor complex in man; Journal of  Gastroenterology; 1979; 14;663-667.
11) Whitehead L, Fell J.T, Collett J.H; Development of a gastroretentive dosage form; European Journal of Pharmaceutical Sciences; 1996; 4(1); 182.
12) Wilson C.G, Washington N; The stomach: its role in oral drug delivery. In: physiological pharmaceutical biological barriers to drug absorption. Chichester, UK: Ellis Horwood; 1989; 47-70.
13) Xu W.L, Tu X.D, Lu Z.D; Develpoment of Gentamycin sulfate sustained release tablets remaining-floating in stomach; AAPS Pharm Tech;1991; 26(7); 541-545.
14) Yang L, Eshraghi J, Fassihi R; A new intragasrtic delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation; Journal of Controlled Release; 1989; 57;215-222.

NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.

SUBMIT YOUR ARTICLE/PROJECT AT editor-in-chief@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email

FIND OUT MORE ARTICLES AT OUR DATABASE


 

Pages

FIND MORE ARTICLES